Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE-SPIRE: Dabigatran vs Warfarin in Massive PE
NCT02979561Phase 4Unknown
- Sponsor
- E. Meshalkin National Medical Research Centre
- Start
- Oct 2016
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dabigatran in pulmonary embolism (PE) (2 arms), sponsored by E. Meshalkin National Medical Research Centre. Primary endpoints: recurrent pulmonary embolism at 6 months and death at 6 months. Status: unknown.
02
Drugs
dabigatran
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT02979561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02979561.